A selective neuronal potassium channel (KCNQ/KV7 channel) activator that also has indirect NMDA receptor antagonist and GABAA receptor modulatory properties.

A potent, selective, orally bioavailable inhibitor of EZH2 with Ki of < 3 nM.

A potent, selective, brain penetrant and orally active mGluR1 antagonist with 4.3 nM and 3.6 nM for huam and rat mGluR1, respectively.

A potent, selective presynaptic dopamine autoreceptor antagonist.

A potent, selective LTA4H (Leukotriene A4 hydrolase) inhibitor (IC50/Kd=47/25 nM) of leukotriene B4 biosynthesis.

A potent, peptide-inhibitor of human chymase with Ki of 1 nM.

A potent inhibitors of Botulinum Neurotoxin A (BoNT) Light Chain with IC50 of 0.9 uM..

A potent and orally active non-peptide C5a receptor (CD88.

A highly potent and selective platelet activating factor (PAF) antagonist.

A diastereomer form of Taranabant, which is a potent, selective and orally active cannabinoid-1 receptor (CB1R) inverse agonist.

A cell-permeable peptide inhibitor of JNK kinase.

(S)-Mapracorat is a selective and less active glucocorticoid receptor agonist.

Z-LEHD-FMK is a cell-permeable, competitive and irreversible inhibitor of enzyme caspase-9, which helps in cell survival.

Y06137 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with a Kd of 81 nM. Antitumor activity.

Y06036 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with Kd value of 82 nM. Antitumor activity.

XMD-18-42 is a NUAK1-sepcific inhibitor.

Tubulin inhibitor 1 is a tubulin inhibitor, occupying the colchicine binding site, inhibits tubulin polymerization. Tubulin inhibitor 1 shows potent anti-tumor activity, casues cellular mitotic arrest in the G2/M phase, and induces cellular apoptosis.

Trk-IN-4 is a potent pan-Trk inhibitor in cell-based assays with IC50s of 1.9 nM, 2.6 nM and 1.1 nM for TrkA, TrkB and TrkC, respectively. Anti-hyperalgesic effect.

TM-25659 is a TAZ modulator. Anti-osteoporotic and anti-obesity activities.

The less active enantiomer of GNE-140, inhibits LDHA activity (18-fold less potent that (R)-GNE-140).

TB500-2 is one of the TB500 metabolites. TB500 is a synthetic version of an active region of thymosin β4. TB500 is claimed to promote endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition and decreas

Target Protein-binding moiety 6 hydrochloride is a compound that binds to BRD9, and used for inhibiting BRD9 activity, based on PROTAC.

TAK-828F is a potent, selective, and orally available retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist (binding IC50=1.9 nM, reporter gene IC50=6.1 nM). TAK-828F shows excellent ROR isoforms selectivity (>5000-fold selectivity aga

TAK-700 shows potent inhibitory activity against rat, monkey, and human steroid 17,20-lyase inhibitor with IC50 of 54 nM, 27 nM, and 38 nM, respectively.

SW-163D-AcLysValCit-PABC-DMAE is a Drug-Linker Conjugates for ADC which consists of a natural bis-intercalator, SW-163D, conjugated via an AcLysValCitPABC-DMAE linker.

SRPKIN-1 is a covalent and irreversible SRPK1/2 inhibitor with IC50s of 35.6 and 98 nM, respectively. Anti-angiogenesis effect.

SHR-1977 is a novel ROMK/hERG inhibitor, (ROMK IC50 = 44 nM, hERG IC50 = >100,000 nM)

Sauristolactam, a natural aristolactam isolated from aerial portions of Saururus chinensis, has significant neuroprotective activity against glutamate-induced toxicity in primary cultured rat cortical cells. Sauristolactam also inhibits the receptor activ

BL-AD008 (BL-AD 008) is a novel small molecule, dual-target activator targeting AMPK/ZIPK; demonstrates remarkable anti-proliferative activities toward cervical cancer cells and could induce apoptosis by death-receptor and mitochondrial pathways; also sho